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1. Introduction
The future of selective internal radiation therapy (SIRT)
in metastatic colorectal cancer (mCRC) and other liver-
dominant cancers will be determined by the ﬁndings
of ongoing prospective phase III trials which will have
the potential to assess not only the acute toxicity but
also the chronic toxicity of SIRT in combination with
chemotherapy early in the treatment paradigm. SIRT
is delivered using yttrium-90 [90Y] loaded microspheres
made of either resin (SIR-Spheres®, Sirtex Medical
Limited, Sydney, Australia) or glass (TheraSphere®,
Nordion, Ottawa, Canada), but in mCRC the evidence for
SIRT is based primarily on 90Y resin microspheres.
2. Personalised dosimetry
While some centres have shown that integration of data
generated by multimodality structural (CT), functional
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(MAA-SPECT) and metabolic (FDG-PET) imaging can
increase the ‘per patient’ beneﬁt of SIRT (and ultimately,
cost-effectiveness) through better preselection of candi-
dates, 1 these facilities are not available to every centre. In
the future, microspheres loaded with new isotopes such
as holmium-166 poly(L-lactic acid) may be developed
as a possible alternative to 90Y microspheres enabling
real-time imaging and dosimetry through quantitative
analysis of the scintigraphic and MR images at the time
of treatment. 2
3. First-line therapy
Candidates for ﬁrst-line therapy with mCRC can be
grouped into three target populations. 1 The ﬁrst are
unresectable patients, who make up the majority
(~75% of patients 3) and for whom the goal of treatment
is to extend survival and maintain quality of life.
The second are patients with potentially resectable
tumours. For these patients, treatments are needed
with high response rates to increase the numbers
eligible for resection. 4 The third group (representing
approximately 25% of patients diagnosed with mCRC 3)
are those who are eligible for resection. The key question
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Fig. 1 – SIR-step clinical study design.
for these patients is whether neoadjuvant treatment
with systemic treatments and/or organ-directed therapy
can improve the long-term outcome by reducing the
likelihood of recurrence.
Current evidence for SIRT in the ﬁrst-line treatment
of mCRC is based on small studies in unresectable liver-
dominant patients. In the future, these studies will be
supported by data from two large phase III randomised
controlled trials (SIRFLOX and FOXFIRE) assessing SIRT
in combination with FOLFOX and biologicals (cetuximab
and/or bevacizumab). These trials will provide important
insights into the interaction of SIRT with chemotherapy
(± biologicals), not only in terms of efﬁcacy but also
safety. As more treatments become available, further
data will be needed on the optimal backbone of systemic
treatment to complement radiotherapy. As indicated
by recent studies with stereotactic body radiotherapy
in head and neck cancer and non-small cell lung
cancer, for example, biological agents, such as cetuximab,
may be sufﬁcient in themselves to enhance activity of
radiotherapy in locally recurrent disease. 5,6 Still to be
answered are critical questions regarding the optimal
timing and dose of the various modern chemotherapy
regimens with biologicals and SIRT to achieve the best
outcomes with the lowest toxicity.
4. Downstaging for resection
Given the high response rate observed with SIRT in
phase II trials in the ﬁrst-line setting 7−10 and the
promising outcomes with chemotherapy plus biologicals
in patients who are potentially resectable, 11 it is hoped
that the SIRFLOX and FOXFIRE trial will:
• quantify the efﬁciency of SIRT plus chemotherapy in
downstaging for R0 resection among patients, who
were initially considered unresectable, but potentially
eligible for SIRT ﬁrst-line
• provide guidance on the optimal timing post-SIRT to
assess best response (as some may achieve a complete
response)
• assess the impact of SIRT on the surgery itself and the
(immediate) postoperative outcome for these patients
5. Consolidation therapy
Beyond the population with potentially resectable
tumours, SIRT might also play a role in consolidating
the response to chemotherapy in cases where patients
are deemed not to be candidates for resection after
assessment of the best response to ﬁrst-line chemo-
therapy. It is known that over time with increasing
numbers of cycles of chemotherapy, tolerance as well
as the safety of treatment decreases. 12 For this reason,
a provisional retrospective analysis was conducted
in 23 patients to assess the efﬁcacy of SIRT as a
consolidation treatment after achieving best response
to ﬁrst-line chemotherapy. The study found that SIRT
enabled patients to have a holiday from systemic
chemotherapy, with 14 of 23 patients (61%) receiving no
chemotherapy for 3 months after SIRT. Progression-free
survival was 6.3 months post-SIRT (or 11.3 months from
the time of ﬁrst-line chemotherapy) and median overall
survival was 23.6 months from the time of initial ﬁrst-
line treatment. 13
Based on these encouraging initial ﬁndings, a phase III
multicentre randomised controlled trial (SIR-step) is
expected to begin soon in collaboration with the
Belgium Group of Digestive Oncology. Patients with
liver-dominant disease will be treated with systemic
chemotherapy ± bevacizumab and treatment response
measured at 3 months. Responders will be randomised
to consolidation chemotherapy with 5-FU ± bevacizumab
with or without SIRT. Following initial progression,
chemotherapy will be re-intensiﬁed (Fig. 1).
6. Second-line in Kras mutant mCRC
In patients with Kras mutant liver-dominant mCRC and
for whom the treatment options are limited, a second
study with SIRT is being sponsored by the IFO in Rome.
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This study, conducted by the Italian Society of Integrated
Locoregional Therapies in Oncology (SITILO-2 trial), will
aim to evaluate the addition of SIRT to standard second-
line therapy in patients with documented progression
following standard ﬁrst-line therapy.
7. Chemorefractory patients
Finally in chemorefractory disease, SIRT with or without
chemotherapy (5-FU as a radiosensitiser) can pro-
long progression-free survival relative to chemotherapy
alone. 14 Importantly, acute toxicity with SIRT appears
to be transient, but the impact of chronic radio-
embolisation-induced liver disease and gastrointestinal
ulcers (although only affecting a minority of patients)
is nevertheless signiﬁcant in the palliative setting. 15
A greater emphasis needs to be placed on reducing the
incidence of these adverse events, 16 and a comparative
multicentre study of safety and efﬁcacy of SIRT plus 5-FU
relative to 5-FU alone in the palliative setting is being
considered.
8. Conclusions
In conclusion, SIRT has become part of the multi-
disciplinary management of patients with mCRC at
many centres. In the future, it is anticipated that a
comprehensive programme of ongoing and planned
trials will further reﬁne the indications for use of
SIRT in mCRC.
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